HSKA 15.90 Heska Corp $HSKA Hit a 52 week high of 16.72

New Post Public Reply Private Reply Replies (0) Message Board

Nov 8, 2014 at 11:59 PM

HSKA 15.90 Heska Corp $HSKA Hit a 52 week high of 16.72 Currently at 15.90 +0.71 +4.67% With a day low of 15.15 and a total volume of 271,100.

HSKA Heska Corp Recent Headline News

Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.02 (-0.03), HSKA: 15.90 (+0.71), ACHN: 10.11 (-0.15), AMAG: 34.95 (+0.83)

Heska Announces Investor Day in New York City
PR Newswire - Tue Nov 04, 8:00AM CST
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, today announced the Company will conduct an Investor Day, from 9 a.m. to noon (EST) on Friday, November 14, 2014. The event will be at the Nasdaq MarketSite in Times Square, located at One Liberty Plaza, 165 Broadway, in New York City.
HSKA: 15.90 (+0.71)

Qiagen Q3 Earnings, Revenues in Line; Outlook Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:50PM CDT
Qiagen's (QGEN) strategic collaborations, test menu expansions and moderately balanced international expansion will likely drive growth over time.
BIIB: 320.75 (-2.72), HSKA: 15.90 (+0.71), ILMN: 186.35 (-3.52), QGEN: 23.48 (-0.20)

Can the Rally in Heska (HSKA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:06AM CDT
Can the Rally in Heska (HSKA) Shares Continue?
HSKA: 15.90 (+0.71)

Heska Reports 24% Revenue Growth, $0.08 Per Share for the Third Quarter of 2014
PR Newswire - Wed Oct 29, 8:00AM CDT
Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, today reported financial results for its third quarter ended September 30, 2014.
HSKA: 15.90 (+0.71)

Heska Signs Distribution Agreement with Henry Schein Animal Health
PR Newswire - Wed Oct 29, 7:45AM CDT
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, announced today a new distribution agreement with Henry Schein Animal Health, the largest companion animal health distribution company in the U.S. Henry Schein Animal Health will market and promote Heska's full line of hematology and chemistry instruments and affiliated consumables, effective immediately.
HSKA: 15.90 (+0.71), HSIC: 128.84 (-1.47)

Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast
PR Newswire - Tue Oct 28, 3:30PM CDT
Heska Corporation (Nasdaq: HSKA) announces the following Webcast:
HSKA: 15.90 (+0.71)

Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:46AM CDT
Repros Therapeutics (RPRX) was a big mover last session, with shares surging almost 17% on the day.
CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), GILD: 106.45 (-0.49), RPRX: 10.12 (+3.67)

Cyclacel Pharmaceuticals (CYCC) in Focus: Stock Jumps 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:21AM CDT
Cyclacel Pharmaceuticals, Inc. (CYCC) was a big mover last session, as the company saw its shares rise by over 5% on the day.
HSKA: 15.90 (+0.71), CBM: 22.66 (-0.82), CYCC: 3.09 (-0.06), GILD: 106.45 (-0.49)

Myriad Genetics Poised on Strong myRisk, Overseas Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 2:20PM CDT
Currently, Myriad Genetics (MYGN) is financing 13 Phase III clinical trials with flagship product BracAnalysis CDx in six different indicated patient populations.
MYGN: 34.89 (+0.11), HSKA: 15.90 (+0.71), CBM: 22.66 (-0.82), GILD: 106.45 (-0.49)

Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 1:50PM CDT
On Sep 25, we issued an updated research report on Qiagen N.V. (QGEN).
HSKA: 15.90 (+0.71), GILD: 106.45 (-0.49), ANTH: 1.84 (-0.02), QGEN: 23.48 (-0.20)

Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:25AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise over 10% on the day.
RNN: 0.71 (+0.01), HSKA: 15.90 (+0.71), CBM: 22.66 (-0.82), GILD: 106.45 (-0.49)

Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:46AM CDT
Dynavax (DVAX) was a big mover last session, with shares rising nearly 7% on the day.
DVAX: 1.59 (unch), HSKA: 15.90 (+0.71), GILD: 106.45 (-0.49), ILMN: 186.35 (-3.52)

Alder Biopharmaceuticals (ALDR) in Focus: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:44AM CDT
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as the company saw its shares rise over 5% on the day.
ALDR: 16.57 (-0.25), CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), ILMN: 186.35 (-3.52)

Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 2:30PM CDT
On Sep 16, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN).
HSKA: 15.90 (+0.71), GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), ILMN: 186.35 (-3.52)

Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:44AM CDT
Dendreon Corp. (DNDN) was a big mover last session, as the company saw its shares rise over 9% on the day
CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), DNDN: 0.94 (+0.11), ILMN: 186.35 (-3.52)

Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:44AM CDT
Cytokinetics (CYTK) as a big mover last session, as the company saw its shares surge over 17 % on the day
CYTK: 4.10 (-0.15), CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), ILMN: 186.35 (-3.52)

Synthetic Biologics (SYN) Looks Strong: Stock Gains 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:44AM CDT
Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares gain nearly 14% on the day
SYN: 1.49 (+0.07), CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), ILMN: 186.35 (-3.52)

China Biologic Products, Inc. (CBPO) Rises: Stock Jumps 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:32AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise more than 7% on the day.
CBPO: 68.90 (-0.08), HSKA: 15.90 (+0.71), CBM: 22.66 (-0.82), GILD: 106.45 (-0.49)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

MV Transportation Celebrates Leadership Nomination for FTA

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Class Action Greenlighted Against Concordia for Title IX Violations

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

WeFetch AI: A New Era in Barcode Precision

By Logan Wright Updated Nov 13, 2026 Category News Views 201

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

vVARDIS Debuts on NYSE: Transforming Dental Care

A New Chapter for Dental Tech Mark your calendars, folks. vVARDIS is stepping onto the New York Stock Exchange (NYSE) stage, waving the banner of NYSE:VVVV. Now, if you've ever sat in that squeaky dental chair feeling the dread of a drill, vVARDIS might just be the new hero in town. Founded by the dynamic duo, Dr. Haley and Dr. Goly Abivardi, they're on a mission to...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...